BioSpace News Archive

The new company, which was founded earlier this year, will take a similar approach to treat kidney disease that oncologists have taken with cancer.

Eli Lilly won an arbitration hearing over accusations the Indianapolis-based company misused confidential information regarding the intellectual property of its former business partner, France-based Adocia S.A.

Researchers at the University of California at San Francisco have discovered that a scorpion toxin can actually be harnessed to target the wasabi receptor, which is described as a “chemical-sensing protein” found in nerve cells.

Researchers from Mount Sinai conducted a study of selinexor with dexamethasone in patients with multiple myeloma who have not responded to previous treatments and the results were quite promising.

In a head-to-head study, BeyondSpring’s plinabulin stood up to Amgen’s Neulasta (pegfilgrastim) in a quality of life study to prevent neutropenia, a common side effect for chemotherapy patients.

Leaders from across the pharmaceutical industry are decrying negative actions taken by government agencies and universities against Chinese researchers in the United States.

ESSA Pharma Inc. (NASDAQ: EPIX; TSXV: EPI) (“ESSA” or the “Company”), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, is pleased to announce a public offering of equity securities of the Company in Canada and a concurrent private placement of equity securities in the United States (the “Offering”).

This week the nationally recognized behavioral health provider FHE Health announced that Dr. Sachi Ananda, Ph.D., LMHC, MCAP, is the new director of the organization’s “Shatterproof” program, a specialized treatment option for police officers, firefighters, correctional officers, EMTs, 911 dispatchers and other first responders.

The idea of walking, running or cycling one million miles sounds quite ambitious – if not impossible – but nothing was impossible to Alexandra “Alex” Scott (1996-2004), who knew that if everyone pitched in to host lemonade stands, they could raise $1 million for childhood cancer research and better, less toxic treatments

NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a clinical stage biotechnology company focused on developing transformative therapeutics for patients, today provided a business update and reported second quarter 2019 financial results for the period ending June 30, 2019.